MODAFINIL

Details

Stereochemistry	RACEMIC
Molecular Formula	C15H15NO2S
Molecular Weight	273.35
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC(=O)C[S+]([O-])C(C1=CC=CC=C1)C2=CC=CC=C2

InChI

InChIKey=YFGHCGITMMYXAQ-UHFFFAOYSA-N

InChI=1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)

HIDE SMILES / InChI

Description
Sources: http://www.drugbank.ca/drugs/DB00745https://www.ncbi.nlm.nih.gov/pubmed/19689169
Curator's Comment: Description was created based on several sources, including https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021875s023lbl.pdf | https://www.drugs.com/pro/armodafinil.html

Armodafinil is the R-enantiomer of modafinil, a wake-promoting agent, that primarily affects areas of the brain involved in controlling wakefulness. Armodafinil is an indirect dopamine receptor agonist; both armodafinil and modafinil bind in vitro to the dopamine transporter and inhibit dopamine reuptake. Armodafinil tablets are indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Once-daily armodafinil was generally well tolerated in adult patients with excessive sleepiness associated with OSA (despite treatment of the underlying condition), narcolepsy or SWSD.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Cytochrome P450 2C19 51 Target ID: CHEMBL3622 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26338061	Inhibitor 8297	51.79 µM [IC50]
Cytochrome P450 2C19 51 Target ID: CHEMBL3622 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26338061	Inhibitor 8297	51.79 µM [IC50]
Dopamine transporter 180 Target ID: CHEMBL238 Sources: http://www.drugbank.ca/drugs/DB00745	Inhibitor 8297	13.0 µM [Ki]
Dopamine transporter 180 Target ID: CHEMBL238 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021875s023lbl.pdf	Inhibitor 8297	4.0 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Narcolepsy 20 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020717A_Provigil_prntlbl.pdf	Primary	Approved 8429	PROVIGIL Approved Use Provigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD). Launch Date 1998
Obstructive sleep apnea 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020717A_Provigil_prntlbl.pdf	Primary	Approved 8429	PROVIGIL Approved Use Provigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD). Launch Date 1998
Sleep disorder 20 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19689169	Primary	Approved 8429	NUVIGIL Approved Use NUVIGIL is indicated to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea, narcolepsy and shift work disorder. In OSA, NUVIGIL is indicated as an adjunct to standard treatment(s) for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating NUVIGIL. If NUVIGIL is used adjunctively with CPAP, the encouragement of and periodic assessment of CPAP compliance is necessary. In all cases, careful attention to the diagnosis and treatment of the underlying sleep disorder(s) is of utmost importance. Prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness. The effectiveness of NUVIGIL in long-term use (greater than 12 weeks) has not been systematically evaluated in placebo-controlled trials. The physician who elects to prescribe NUVIGIL for an extended time in patients should periodically re-evaluate long-term usefulness for the individual patient. Launch Date 2007

C_max

Value	Dose	Analyte	Population
7.4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
10.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	250 mg 1 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
10 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
13.4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.8 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
4.1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
105.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
136.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	250 mg 1 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
150.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
189.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
23.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
56.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
142.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
146 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
15.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
40.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
43.8 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
75.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
13.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
150 mg 1 times / day steady, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29734973	unhealthy, 21 years n = 1 Health Status: unhealthy Condition: idiopathic hypersomnia Age Group: 21 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/29734973	Disc. AE: Stevens-Johnson syndrome... AEs leading to discontinuation/dose reduction: Stevens-Johnson syndrome (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/29734973
400 mg single, oral Highest studied dose Dose: 400 mg Route: oral Route: single Dose: 400 mg Sources: https://pubmed.ncbi.nlm.nih.gov/19133704	healthy, 21–40 years n = 6 Health Status: healthy Age Group: 21–40 years Sex: M Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/19133704	Sources: https://pubmed.ncbi.nlm.nih.gov/19133704
400 mg 1 times / day steady, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19133704	healthy, 21–40 years n = 4 Health Status: healthy Age Group: 21–40 years Sex: M Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/19133704	Disc. AE: Adverse event... AEs leading to discontinuation/dose reduction: Adverse event Sources: https://pubmed.ncbi.nlm.nih.gov/19133704
150 mg 1 times / day steady, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf	unhealthy n = 645 Health Status: unhealthy Population Size: 645 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf	Disc. AE: Headache... AEs leading to discontinuation/dose reduction: Headache (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf
150 mg 1 times / day steady, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6	unhealthy n = 645 Health Status: unhealthy Population Size: 645 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6	Disc. AE: Rash, Angioneurotic edema... AEs leading to discontinuation/dose reduction: Rash (2%) Angioneurotic edema (1%) Hyperhidrosis (1%) Rash papular (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6

AEs

AE	Significance	Dose	Population
Stevens-Johnson syndrome	1 patient Disc. AE	150 mg 1 times / day steady, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29734973	unhealthy, 21 years n = 1 Health Status: unhealthy Condition: idiopathic hypersomnia Age Group: 21 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/29734973
Adverse event	Disc. AE	400 mg 1 times / day steady, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19133704	healthy, 21–40 years n = 4 Health Status: healthy Age Group: 21–40 years Sex: M Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/19133704
Headache	1% Disc. AE	150 mg 1 times / day steady, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf	unhealthy n = 645 Health Status: unhealthy Population Size: 645 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf
Angioneurotic edema	1% Disc. AE	150 mg 1 times / day steady, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6	unhealthy n = 645 Health Status: unhealthy Population Size: 645 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6
Hyperhidrosis	1% Disc. AE	150 mg 1 times / day steady, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6	unhealthy n = 645 Health Status: unhealthy Population Size: 645 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6
Rash papular	1% Disc. AE	150 mg 1 times / day steady, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6	unhealthy n = 645 Health Status: unhealthy Population Size: 645 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6
Rash	2% Disc. AE	150 mg 1 times / day steady, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6	unhealthy n = 645 Health Status: unhealthy Population Size: 645 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:77590	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:77590
ZINC	ZINC000003831139	http://zinc15.docking.org/substances/ZINC000003831139

PubMed

Title	Date	PubMed
		252160029
Non-amphetaminic mechanism of stimulant locomotor effect of modafinil in mice.	1995 Dec	8998404
Dopaminergic role in stimulant-induced wakefulness.	2001 Mar 1	11222668
Differential enhancement of dialysate serotonin levels in distinct brain regions of the awake rat by modafinil: possible relevance for wakefulness and depression.	2002 Apr 1	11933055
Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study.	2002 Aug	12195441
The SK-N-MC cell line expresses an orexin binding site different from recombinant orexin 1-type receptor.	2002 Feb	11856342
Effect of modafinil at steady state on the single-dose pharmacokinetic profile of warfarin in healthy volunteers.	2002 Feb	11831544
Maintaining alertness and performance during sleep deprivation: modafinil versus caffeine.	2002 Jan	11862356
Narcolepsy and psychopathology: is there an association?	2002 Jul	14592199
Gateways to clinical trials.	2002 Jul-Aug	12224444
Modafinil in the treatment of depression with severe comorbid medical illness.	2002 Jul-Aug	12189262
Gateways to Clinical Trials. June 2002.	2002 Jun	12168506
Study of the addictive potential of modafinil in naive and cocaine-experienced rats.	2002 Jun	12073166
Clinical applications of modafinil in stimulant abusers: low abuse potential.	2002 Summer	12202017
Temporal pattern of hippocampal high-frequency oscillations during sleep after stimulant-evoked waking.	2003	14568034
Fatigue in multiple sclerosis: definition, pathophysiology and treatment.	2003	12665396
[Therapy of day time fatigue in patients with multiple sclerosis].	2003	12658965
Chiral analysis of d- and l-modafinil in human serum: application to human pharmacokinetic studies.	2003 Apr	12657914
Modafinil in children with attention-deficit hyperactivity disorder.	2003 Aug	14580657
TetraTab--cognitive enhancement gone wrong.	2003 Aug	12878430
Pharmacogenomics in the treatment of narcolepsy.	2003 Jan	12517283
Pro: modafinil has a role in management of sleep apnea.	2003 Jan 15	12524247
Modafinil for treatment of cognitive side effects of antiepileptic drugs in a patient with seizures and stroke.	2003 Jun	12791341
Modafinil treatment of opioid-induced sedation.	2003 Jun	12873263
Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy.	2003 Jun	12798791
Cataplexy worsened by modafinil.	2003 Jun 15	12841378
Modafinil increases histamine release in the anterior hypothalamus of rats.	2003 Mar 20	12614915
Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study.	2003 May 1	12681523
The safety and efficacy of modafinil in multiple sclerosis-related fatigue.	2003 Oct	13678557
Narcolepsy drug could be approved for wider use.	2003 Oct 4	14558511
The quest for a smart pill.	2003 Sep	12951828
You'll lose sleep over this pill.	2003 Sep 29	14521093
Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy.	2003 Sep-Oct	14520165
Anti-narcoleptic agent modafinil and its sulfone: a novel facile synthesis and potential anti-epileptic activity.	2004 Aug	15260124
Modafinil treatment of excessive sedation associated with divalproex sodium.	2004 Jan	14763681
Piperidine-based nocaine/modafinil hybrid ligands as highly potent monoamine transporter inhibitors: efficient drug discovery by rational lead hybridization.	2004 Nov 18	15537337
A double-blind, placebo-controlled trial of modafinil for cocaine dependence.	2005 Jan	15525998
Prediction of genotoxicity of chemical compounds by statistical learning methods.	2005 Jun	15962942
Modafinil for excessive sleepiness associated with chronic shift work sleep disorder: effects on patient functioning and health-related quality of life.	2007	17632651
Psychostimulants and military operations.	2007 Apr	17484308
Hyperprolactinemia and galactorrhea induced by serotonin and norepinephrine reuptake inhibiting antidepressants.	2007 Jul	17606668
Smoked cocaine self-administration is decreased by modafinil.	2008 Mar	17568397
Open-label pilot study of modafinil for methamphetamine dependence.	2009 Oct	19745650
[Modafinil in psychiatric disorders: the promising state reconsidered].	2010	21064019
Modafinil effects on reinstatement of methamphetamine seeking in a rat model of relapse.	2010 Jun	20352413
Normalizing effects of modafinil on sleep in chronic cocaine users.	2010 Mar	20080983
Modafinil for bipolar depression with comorbid methamphetamine abuse.	2010 Mar-Apr	20163392
A retrospective review of supratherapeutic modafinil exposures.	2010 Sep	20358418
Armodafinil in the treatment of sleep/wake disorders.	2010 Sep 7	20856606
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.	2015 May 18	25811541

Patents

Sample Use Guides

In Vivo Use Guide

Dosage in Narcolepsy and Obstructive Sleep Apnea (OSA) The recommended dosage of PROVIGIL (Modafinil ) for patients with narcolepsy or OSA is 200 mg taken orally once a day as a single dose in the morning.

Route of Administration: Oral

In Vitro Use Guide

At high concentrations of modafinil (>/=100 uM), the mean activity of CYP2C9 in pooled human liver microsomes was decreased (up to 60%) relative to that in the solvent controls.

Name

Type

Language

MODAFINIL

Official Name

English

NSC-759110

Code

English

CEP-1538

Code

English

THN-102 COMPONENT MODAFINIL

Code

English

CEP 1538

Code

English

ACETAMIDE, 2-((DIPHENYLMETHYL)SULFINYL)-

Systematic Name

English

MODAFINIL [MART.]

Common Name

English

DEP-1538

Code

English

CRL 40476

Code

English

NSC-751178

Code

English

MODAFINIL [USP MONOGRAPH]

Common Name

English

(±)-MODAFINIL

Common Name

English

CRL-40476

Code

English

THN102 COMPONENT MODAFINIL

Code

English

MODAFINIL [USAN]

Common Name

English

2-[(Diphenylmethyl)sulfinyl]acetamide

Systematic Name

English

CRC-40476

Code

English

MODIODAL

Brand Name

English

Modafinil [WHO-DD]

Common Name

English

MODAFINIL [JAN]

Common Name

English

modafinil [INN]

Common Name

English

MODAFINIL CIV

Common Name

English

MODAFINIL [EP MONOGRAPH]

Common Name

English

MODAFINIL [HSDB]

Common Name

English

MODAPHONIL

Brand Name

English

PROVIGIL

Brand Name

English

MODAFINIL [MI]

Common Name

English

MODAFINIL CIV [USP-RS]

Common Name

English

MODAFINIL [VANDF]

Common Name

English

MODAFINIL [ORANGE BOOK]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C47795